| scholarly article | Q13442814 |
| P50 | author | John Anthony Hardy | Q6237755 |
| Jason L. Eriksen | Q56000546 | ||
| Lisa Skipper | Q58001133 | ||
| Dennis W. Dickson | Q30504740 | ||
| Jungsu Kim | Q42371135 | ||
| P2093 | author name string | Georgia Dolios | |
| Rong Wang | |||
| Mike Hutton | |||
| Pritam Das | |||
| Eileen McGowan | |||
| Wen-Lang Lin | |||
| Christopher B Eckman | |||
| Todd Golde | |||
| Fiona Pickford | |||
| M Paul Murphy | |||
| Cindy Yu | |||
| Karen Jansen | |||
| Michael DeLucia | |||
| Luisa Onstead | |||
| Jenny Beard | |||
| P2860 | cites work | A stop-codon mutation in the BRI gene associated with familial British dementia | Q22010197 |
| Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice | Q22242267 | ||
| Interaction of human and mouse Abeta peptides | Q81109116 | ||
| Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein | Q22251280 | ||
| Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease | Q24564815 | ||
| Pathways towards and away from Alzheimer's disease | Q24596270 | ||
| A decamer duplication in the 3' region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred | Q24675956 | ||
| Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo | Q24683214 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia | Q28346149 | ||
| The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease | Q28610089 | ||
| High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation | Q29616564 | ||
| The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease | Q30432239 | ||
| Characterization of amyloid beta peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein | Q31128115 | ||
| Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. | Q31840691 | ||
| Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease | Q33971351 | ||
| Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. | Q34341174 | ||
| Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease | Q34415666 | ||
| Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes | Q34452028 | ||
| Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease | Q34988301 | ||
| Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease | Q35084110 | ||
| Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons | Q36324215 | ||
| Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology | Q36724967 | ||
| Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease | Q36784564 | ||
| The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry | Q36835366 | ||
| Expression of BRI-amyloid beta peptide fusion proteins: a novel method for specific high-level expression of amyloid beta peptides | Q40789655 | ||
| Alzheimer's disease: genetic studies and transgenic models | Q40826156 | ||
| A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor | Q40890347 | ||
| Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? | Q40918121 | ||
| The role of A beta 42 in Alzheimer's disease | Q42463004 | ||
| The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice | Q43889957 | ||
| BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease | Q44722202 | ||
| Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). | Q48092766 | ||
| Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. | Q48601563 | ||
| Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. | Q48933018 | ||
| Amyloidogenesis in familial British dementia is associated with a genetic defect on chromosome 13. | Q49011608 | ||
| Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). | Q53201871 | ||
| Interaction between A beta(1-42) and A beta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro. | Q53231526 | ||
| A vector for expressing foreign genes in the brains and hearts of transgenic mice | Q54965153 | ||
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 191-199 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | Neuron | Q3338676 |
| P1476 | title | Abeta42 is essential for parenchymal and vascular amyloid deposition in mice | |
| P478 | volume | 47 |
| Q37232572 | 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease |
| Q55514800 | 7B2 chaperone knockout in APP model mice results in reduced plaque burden. |
| Q90732117 | A Human Embryonic Stem Cell Model of Aβ-Dependent Chronic Progressive Neurodegeneration |
| Q87928814 | A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation |
| Q31041418 | A new structural model of Alzheimer's Aβ42 fibrils based on electron paramagnetic resonance data and Rosetta modeling |
| Q30579707 | A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice |
| Q46813624 | A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. |
| Q30455082 | APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD). |
| Q42674921 | APP-BP1 inhibits Abeta42 levels by interacting with Presenilin-1. |
| Q33572654 | Aberrant amyloid precursor protein (APP) processing in hereditary forms of Alzheimer disease caused by APP familial Alzheimer disease mutations can be rescued by mutations in the APP GxxxG motif |
| Q48305645 | Abeta40 inhibits amyloid deposition in vivo. |
| Q35016226 | Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology |
| Q24317730 | Abeta42-to-Abeta40- and angiotensin-converting activities in different domains of angiotensin-converting enzyme |
| Q35075741 | Acceleration of amyloid beta-peptide aggregation by physiological concentrations of calcium |
| Q24299193 | Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry |
| Q28828789 | Aftins increase amyloid-β42, lower amyloid-β38, and do not alter amyloid-β40 extracellular production in vitro: toward a chemical model of Alzheimer's disease? |
| Q33712475 | Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease |
| Q48433781 | Age-related modulation of γ-secretase activity in non-human primate brains. |
| Q35256535 | Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics |
| Q34219814 | Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy |
| Q92508451 | Alborixin clears amyloid-β by inducing autophagy through PTEN-mediated inhibition of the AKT pathway |
| Q22251262 | Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain |
| Q37124928 | Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease |
| Q37028176 | Alzheimer's Aβ42 and Aβ40 peptides form interlaced amyloid fibrils |
| Q37671455 | Alzheimer's disease and the amyloid-beta peptide |
| Q27005935 | Alzheimer's disease, amyloid peptide and synaptic dysfunction |
| Q36577655 | Alzheimer's disease, brain immune privilege and memory: a hypothesis |
| Q57074482 | Alzheimer's disease, estrogens, and clinical trials: a case study in drug development for complex disorders |
| Q35687044 | Alzheimer's disease: pathological mechanisms and recent insights |
| Q37862502 | Alzheimer's disease: the challenge of the second century |
| Q42034358 | Amide solvent protection analysis demonstrates that amyloid-beta(1-40) and amyloid-beta(1-42) form different fibrillar structures under identical conditions |
| Q46002406 | Amyloid Accumulation Drives Proteome-wide Alterations in Mouse Models of Alzheimer's Disease-like Pathology. |
| Q37002863 | Amyloid Beta peptides differentially affect hippocampal theta rhythms in vitro |
| Q30489361 | Amyloid precursor protein-induced axonopathies are independent of amyloid-beta peptides |
| Q40162528 | Amyloid β peptides overexpression in retinal pigment epithelial cells via AAV-mediated gene transfer mimics AMD-like pathology in mice |
| Q39144650 | Amyloid β peptides promote autophagy-dependent differentiation of mouse neural stem cells: Aβ-mediated neural differentiation. |
| Q27012950 | Amyloid β precursor protein as a molecular target for amyloid β--induced neuronal degeneration in Alzheimer's disease |
| Q34451907 | Amyloid-beta: a crucial factor in Alzheimer's disease. |
| Q90317165 | Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer's disease |
| Q48497465 | An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer's Disease. |
| Q35159081 | An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. |
| Q30316057 | An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice |
| Q36976873 | An update of animal models of Alzheimer disease with a reevaluation of plaque depositions |
| Q80768190 | Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition |
| Q38045853 | Animal models of Alzheimer disease |
| Q37196122 | Animal models of Alzheimer's disease and frontotemporal dementia |
| Q34097190 | Animal models of amyloid-beta-related pathologies in Alzheimer's disease |
| Q57143848 | Animal models of neurodegenerative diseases |
| Q34195981 | Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model |
| Q28477320 | Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease |
| Q47833979 | Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer's disease model |
| Q35924931 | ApoER2 expression increases Abeta production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of gamma-secretase activity. |
| Q34628212 | Apolipoprotein E in synaptic plasticity and Alzheimer's disease: potential cellular and molecular mechanisms |
| Q92583989 | Apolipoprotein E4: A Risk Factor for Successful Cognitive Aging |
| Q42002912 | Aβ Peptide Originated from Platelets Promises New Strategy in Anti-Alzheimer's Drug Development. |
| Q41961695 | Aβ aggregation profiles and shifts in APP processing favor amyloidogenesis in canines |
| Q41873573 | Aβ degradation-the inside story |
| Q39293031 | Aβ oligomer toxicity inhibitor protects memory in models of synaptic toxicity |
| Q38505163 | Aβ42 and Aβ40: similarities and differences |
| Q33643141 | BACE1 and BACE2 enzymatic activities in Alzheimer's disease |
| Q35917682 | BACE2 expression increases in human neurodegenerative disease |
| Q24319041 | BRI2 (ITM2b) inhibits Abeta deposition in vivo |
| Q26858963 | Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines |
| Q42040291 | Bifunctional compounds for controlling metal-mediated aggregation of the aβ42 peptide |
| Q96129239 | Biophysical studies of protein misfolding and aggregation in in vivo models of Alzheimer's and Parkinson's diseases |
| Q46081295 | Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. |
| Q34091893 | Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease |
| Q42066595 | Building a better blood-brain barrier. |
| Q30483651 | C-terminal peptides coassemble into Abeta42 oligomers and protect neurons against Abeta42-induced neurotoxicity |
| Q40179990 | Calcineurin/NFAT Signaling in Activated Astrocytes Drives Network Hyperexcitability in Aβ-Bearing Mice |
| Q46890505 | Carnosine protects against Abeta42-induced neurotoxicity in differentiated rat PC12 cells. |
| Q47333744 | Cell-type Dependent Alzheimer's Disease Phenotypes: Probing the Biology of Selective Neuronal Vulnerability. |
| Q91892434 | Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways |
| Q37019428 | Cerebral amyloid angiopathy and parenchymal amyloid deposition in transgenic mice expressing the Danish mutant form of human BRI2. |
| Q34889214 | Cerebral amyloid angiopathy increases susceptibility to infarction after focal cerebral ischemia in Tg2576 mice |
| Q37186592 | Cerebral amyloid angiopathy: progressive disruption of the neurovascular unit |
| Q90657534 | Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E |
| Q35848336 | Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator. |
| Q33291589 | Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice |
| Q34919663 | Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. |
| Q34071954 | Circulating neprilysin clears brain amyloid |
| Q42064039 | Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels. |
| Q90593525 | Cofilin, a Master Node Regulating Cytoskeletal Pathogenesis in Alzheimer's Disease |
| Q37434914 | Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. |
| Q38609997 | Cognitive impairment in humanized APP×PS1 mice is linked to Aβ(1-42) and NOX activation. |
| Q44413015 | Common Impact of Chronic Kidney Disease and Brain Microhemorrhages on Cerebral Aβ Pathology in SHRSP. |
| Q41971448 | Comparative pathobiology of β-amyloid and the unique susceptibility of humans to Alzheimer's disease |
| Q34058840 | Comparison of Abeta levels in the brain of familial and sporadic Alzheimer's disease |
| Q38737649 | Complex relationships between substrate sequence and sensitivity to alterations in γ-secretase processivity induced by γ-secretase modulators |
| Q42942994 | Cortical neurons transgenic for human Abeta40 or Abeta42 have similar vulnerability to apoptosis despite their different amyloidogenic properties |
| Q44369500 | Cross-seeding between Aβ40 and Aβ42 in Alzheimer's disease |
| Q22241945 | Current Insights into Molecular Mechanisms of Alzheimer Disease and Their Implications for Therapeutic Approaches |
| Q60310921 | Current state of Alzheimer's fluid biomarkers |
| Q35831042 | Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model |
| Q30443526 | Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer's disease |
| Q34974913 | Deficiency of patched 1-induced Gli1 signal transduction results in astrogenesis in Swedish mutated APP transgenic mice |
| Q48592298 | Deletion of presenilin 1 hydrophilic loop sequence leads to impaired gamma-secretase activity and exacerbated amyloid pathology. |
| Q89234809 | Dependence of the Formation of Tau and Aβ Peptide Mixed Aggregates on the Secondary Structure of the N-Terminal Region of Aβ |
| Q37381344 | Differences in the cellular uptake and intracellular itineraries of amyloid beta proteins 40 and 42: ramifications for the Alzheimer's drug discovery |
| Q39398322 | Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice |
| Q27305237 | Dimer formation enhances structural differences between amyloid β-protein (1-40) and (1-42): an explicit-solvent molecular dynamics study |
| Q36298522 | Discovery and structure activity relationship of small molecule inhibitors of toxic β-amyloid-42 fibril formation |
| Q39511082 | Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable γ-Secretase Modulator |
| Q34498158 | Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa |
| Q47665801 | Disruption of amyloid precursor protein ubiquitination selectively increases amyloid β (Aβ) 40 levels via presenilin 2-mediated cleavage |
| Q36981858 | Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study |
| Q91607278 | Diversity in Aβ deposit morphology and secondary proteome insolubility across models of Alzheimer-type amyloidosis |
| Q101051196 | Dynamic changes in the brain protein interaction network correlates with progression of Aβ42 pathology in Drosophila |
| Q38194496 | Dysfunctional autophagy in Alzheimer's disease: pathogenic roles and therapeutic implications |
| Q36587065 | Early brain injury alters the blood-brain barrier phenotype in parallel with β-amyloid and cognitive changes in adulthood |
| Q34203241 | Early calcium dysregulation in Alzheimer's disease: setting the stage for synaptic dysfunction |
| Q33988701 | Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial |
| Q34020429 | Effects of nonsteroidal anti-inflammatory drugs on amyloid-beta pathology in mouse skeletal muscle |
| Q37356689 | Effects of short-term Western diet on cerebral oxidative stress and diabetes related factors in APP x PS1 knock-in mice. |
| Q36998748 | Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models |
| Q39457919 | Enzymatic characteristics of I213T mutant presenilin-1/gamma-secretase in cell models and knock-in mouse brains: familial Alzheimer disease-linked mutation impairs gamma-site cleavage of amyloid precursor protein C-terminal fragment beta |
| Q33713881 | Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease |
| Q93181542 | Facilitation of glutamate, but not GABA, release in Familial Alzheimer's APP mutant Knock-in rats with increased β-cleavage of APP |
| Q46642854 | Familial Danish dementia: co-existence of Danish and Alzheimer amyloid subunits (ADan AND A{beta}) in the absence of compact plaques |
| Q41663079 | G206D Mutation of Presenilin-1 Reduces Pen2 Interaction, Increases Aβ42/Aβ40 Ratio and Elevates ER Ca(2+) Accumulation. |
| Q30827278 | Gender-Specific Hippocampal Dysrhythmia and Aberrant Hippocampal and Cortical Excitability in the APPswePS1dE9 Model of Alzheimer's Disease |
| Q37542635 | Genetic animal models of cerebral vasculopathies |
| Q33747695 | Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies |
| Q38427356 | Glutamate receptors function as scaffolds for the regulation of β-amyloid and cellular prion protein signaling complexes. |
| Q33276402 | GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. |
| Q37188278 | Hereditary and sporadic forms of abeta-cerebrovascular amyloidosis and relevant transgenic mouse models |
| Q47738177 | Hesperidin alleviates cognitive impairment, mitochondrial dysfunction and oxidative stress in a mouse model of Alzheimer's disease |
| Q57214783 | Highly sensitive/selective 3D nanostructured immunoparticle-based interface on a multichannel sensor array for detecting amyloid-beta in Alzheimer's disease |
| Q24338827 | Human APOE genotype affects intraneuronal Aβ1-42 accumulation in a lentiviral gene transfer model |
| Q58761831 | Human Alzheimer's disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology |
| Q40450053 | Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer's disease and related dementias. |
| Q89642624 | Identification of early pericyte loss and vascular amyloidosis in Alzheimer's disease retina |
| Q38198632 | Imaging of cerebrovascular pathology in animal models of Alzheimer's disease |
| Q30493196 | Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease |
| Q48213352 | Immune cells may fend off Alzheimer disease |
| Q37655247 | Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. |
| Q26745928 | Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges |
| Q38917669 | In silico investigation on the inhibition of Aβ42 aggregation by Aβ40 peptide by potential of mean force study |
| Q36291634 | In vitro and in vivo degradation of Abeta peptide by peptidases coupled to erythrocytes |
| Q35182808 | Increased fragmentation of sleep-wake cycles in the 5XFAD mouse model of Alzheimer's disease |
| Q35371482 | Independent relationship between amyloid precursor protein (APP) dimerization and γ-secretase processivity |
| Q21136406 | Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease |
| Q37253971 | Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta} |
| Q30438461 | Interprotofilament interactions between Alzheimer's Abeta1-42 peptides in amyloid fibrils revealed by cryoEM |
| Q36115160 | Intracellular amyloid precursor protein sorting and amyloid-β secretion are regulated by Src-mediated phosphorylation of Mint2 |
| Q43913392 | Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. |
| Q35246412 | Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease |
| Q48404445 | Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. |
| Q30319326 | Isoaspartate-containing amyloid precursor protein-derived peptides alter efficacy and specificity of potential beta-secretases |
| Q24676498 | Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease |
| Q37707829 | Mapping superoxide dismutase 1 domains of non-native interaction: roles of intra- and intermolecular disulfide bonding in aggregation |
| Q33245678 | Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. |
| Q36448521 | Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models |
| Q33568378 | Membrane localization of beta-amyloid 1-42 in lysosomes: a possible mechanism for lysosome labilization |
| Q46963608 | Membrane-anchored Aβ accelerates amyloid formation and exacerbates amyloid-associated toxicity in mice. |
| Q30580280 | Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease |
| Q42156626 | MiR-106b impairs cholesterol efflux and increases Aβ levels by repressing ABCA1 expression. |
| Q47206608 | Model membrane size-dependent amyloidogenesis of Alzheimer's amyloid-β peptides |
| Q47961713 | Modeling Amyloid-β42 Toxicity and Neurodegeneration in Adult Zebrafish Brain |
| Q36448525 | Modeling familial British dementia in transgenic mice |
| Q35023109 | Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family |
| Q38941268 | Modulation of the Aβ peptide aggregation pathway by KP1019 limits Aβ-associated neurotoxicity. |
| Q39355183 | Molecular Pathogenesis of Alzheimer's Disease: An Update |
| Q42375937 | Molecular and Cellular Basis of Neurodegeneration in Alzheimer's Disease |
| Q38830933 | Molecular and cellular aspects of age-related cognitive decline and Alzheimer's disease |
| Q38001784 | Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease |
| Q28474877 | Molecular profiling reveals diversity of stress signal transduction cascades in highly penetrant Alzheimer's disease human skin fibroblasts |
| Q34557404 | More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration |
| Q36245638 | Motor Cortex Theta and Gamma Architecture in Young Adult APPswePS1dE9 Alzheimer Mice |
| Q37964886 | Mouse models of Alzheimer's disease |
| Q36278396 | Murine Aβ over-production produces diffuse and compact Alzheimer-type amyloid deposits |
| Q37752915 | Murine models of Alzheimer's disease and their use in developing immunotherapies. |
| Q36270381 | Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models |
| Q35199200 | Myelin basic protein binds to and inhibits the fibrillar assembly of Abeta42 in vitro |
| Q38647131 | Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood-brain barrier model |
| Q37780959 | Neuronal models for studying tau pathology. |
| Q58605243 | Neurovascular dysfunction in vascular dementia, Alzheimer's and atherosclerosis |
| Q36858817 | Normal cognition in transgenic BRI2-Aβ mice |
| Q42247303 | Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels. |
| Q35956077 | Oridonin Attenuates Synaptic Loss and Cognitive Deficits in an Aβ1-42-Induced Mouse Model of Alzheimer's Disease |
| Q36424815 | Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains. |
| Q33936595 | PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease |
| Q35862439 | Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. |
| Q34067152 | Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice |
| Q34127547 | Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model |
| Q34630346 | Pathology associated with AAV mediated expression of beta amyloid or C100 in adult mouse hippocampus and cerebellum |
| Q48559227 | Peripheral treatment with enoxaparin exacerbates amyloid plaque pathology in Tg2576 mice. |
| Q33705401 | Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease |
| Q37947768 | Pharmacological treatment of Alzheimer disease |
| Q36375559 | Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease. |
| Q37403796 | Plasma and cerebrospinal fluid amyloid-β levels in late-life depression: A systematic review and meta-analysis. |
| Q37339418 | Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage. |
| Q36713678 | Postmortem Pittsburgh Compound B (PiB) binding increases with Alzheimer's disease progression. |
| Q39513749 | Potent amyloidogenicity and pathogenicity of Aβ43. |
| Q90399180 | Potential Role of Venular Amyloid in Alzheimer's Disease Pathogenesis |
| Q33912803 | Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics |
| Q53025487 | Preclinical Comparison of the Amyloid-β Radioligands [(11)C]Pittsburgh compound B and [(18)F]florbetaben in Aged APPPS1-21 and BRI1-42 Mouse Models of Cerebral Amyloidosis. |
| Q90275269 | Prominent amyloid plaque pathology and cerebral amyloid angiopathy in APP V717I (London) carrier - phenotypic variability in autosomal dominant Alzheimer's disease |
| Q38682621 | Propagation of Aß pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies |
| Q34110227 | Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process |
| Q34590969 | Protein amyloids develop an intrinsic fluorescence signature during aggregation |
| Q38078868 | Protein quality control system in neurodegeneration: a healing company hard to beat but failure is fatal |
| Q37157432 | Pulsed hydrogen-deuterium exchange mass spectrometry probes conformational changes in amyloid beta (Aβ) peptide aggregation |
| Q64095768 | Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1-40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology |
| Q43288312 | Quantitative reverse-transcription polymerase chain reaction analysis of Alzheimer's-associated genes in mouse scrapie |
| Q22242293 | REVIEW: Curcumin and Alzheimer's Disease |
| Q27694752 | Regulation of distinct pools of amyloid β-protein by multiple cellular proteases |
| Q37285990 | Regulation of intracellular calcium in cortical neurons transgenic for human Abeta40 and Abeta42 following nutritive challenge |
| Q37307236 | Relevance of transgenic mouse models to human Alzheimer disease |
| Q35674780 | Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy |
| Q37013605 | Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis |
| Q58027500 | Rodent models for Alzheimer disease |
| Q47703114 | Role of Amyloid Precursor Protein (APP) and Its Derivatives in the Biology and Cell Fate Specification of Neural Stem Cells |
| Q48912014 | Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation. |
| Q33496258 | Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels |
| Q38315714 | Selenoprotein P and selenoprotein M block Zn2+ -mediated Aβ42 aggregation and toxicity |
| Q34332342 | Sex- and brain region-specific acceleration of β-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease. |
| Q46203407 | Short Aβ peptides attenuate Aβ42 toxicity in vivo. |
| Q38946116 | Small bifunctional chelators that do not disaggregate amyloid β fibrils exhibit reduced cellular toxicity |
| Q36430814 | Small-molecule inducers of Aβ-42 peptide production share a common mechanism of action |
| Q33863420 | Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells |
| Q46828851 | Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. |
| Q28131750 | Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide |
| Q36121757 | Specific Triazine Herbicides Induce Amyloid-β42 Production |
| Q48132206 | Starvation triggers Abeta42 generation from human umbilical vascular endothelial cells |
| Q37118735 | Steroids as γ-secretase modulators |
| Q24631702 | Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils |
| Q35562828 | Substrate sequence influences γ-secretase modulator activity, role of the transmembrane domain of the amyloid precursor protein |
| Q37208440 | Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice |
| Q42148708 | Synergistic effects of long-term antioxidant diet and behavioral enrichment on beta-amyloid load and non-amyloidogenic processing in aged canines |
| Q28546774 | Systematic Aβ Analysis in Drosophila Reveals High Toxicity for the 1-42, 3-42 and 11-42 Peptides, and Emphasizes N- and C-Terminal Residues |
| Q102369181 | TDP-43 interacts with amyloid-β, inhibits fibrillization, and worsens pathology in a model of Alzheimer's disease |
| Q26823723 | TDP-43: a new player on the AD field? |
| Q41387476 | Targeting Apolipoprotein E/Amyloid β Binding by Peptoid CPO_Aβ17-21 P Ameliorates Alzheimer's Disease Related Pathology and Cognitive Decline. |
| Q90049715 | Targeting Autophagy for the Treatment of Alzheimer's Disease: Challenges and Opportunities |
| Q42352469 | Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. |
| Q41985456 | Tau pathogenesis is promoted by Aβ1-42 but not Aβ1-40. |
| Q36950153 | Tauopathy with paired helical filaments in an aged chimpanzee |
| Q90044778 | The Alzheimer's Disease Amyloid-Beta Hypothesis in Cardiovascular Aging and Disease: JACC Focus Seminar |
| Q39584144 | The Effects of Astilbin on Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease |
| Q39291792 | The Exceptional Vulnerability of Humans to Alzheimer's Disease |
| Q35542857 | The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders |
| Q55437462 | The Relation Between Brain Amyloid Deposition, Cortical Atrophy, and Plasma Biomarkers in Amnesic Mild Cognitive Impairment and Alzheimer's Disease. |
| Q26991654 | The airbag problem-a potential culprit for bench-to-bedside translational efforts: relevance for Alzheimer's disease |
| Q28591283 | The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice |
| Q41076513 | The blood clotting Factor XIIIa forms unique complexes with amyloid-beta (Aβ) and colocalizes with deposited Aβ in cerebral amyloid angiopathy |
| Q39101514 | The effect of Cu(2+) and Zn(2+) on the Aβ42 peptide aggregation and cellular toxicity |
| Q30537187 | The effect of PN-1, a Traditional Chinese Prescription, on the Learning and Memory in a Transgenic Mouse Model of Alzheimer's Disease |
| Q36000134 | The mechanism of γ-Secretase dysfunction in familial Alzheimer disease |
| Q48326078 | The pathogenesis of Alzheimer's disease and the role of Abeta42. |
| Q36954095 | The pathogenesis of Alzheimers disease is it a lifelong "calciumopathy"? |
| Q39951771 | The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity |
| Q34603092 | The role of apolipoprotein E in Alzheimer's disease |
| Q33887222 | The secretases: enzymes with therapeutic potential in Alzheimer disease |
| Q53272801 | The solvent protection of alzheimer amyloid-beta-(1-42) fibrils as determined by solution NMR spectroscopy. |
| Q33715954 | The type of Aβ-related neuronal degeneration differs between amyloid precursor protein (APP23) and amyloid β-peptide (APP48) transgenic mice |
| Q37083271 | The value of incomplete mouse models of Alzheimer's disease |
| Q37130346 | Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-β proteins in the cerebral vasculature |
| Q33770749 | Transgenic Drosophila models of Alzheimer's disease and tauopathies |
| Q48691605 | Transgenic expression of intraneuronal Aβ42 but not Aβ40 leads to cellular Aβ lesions, degeneration, and functional impairment without typical Alzheimer's disease pathology. |
| Q33832139 | Transgenic mice overexpressing amyloid precursor protein exhibit early metabolic deficits and a pathologically low leptin state associated with hypothalamic dysfunction in arcuate neuropeptide Y neurons |
| Q82647986 | Transgenic mouse models of Alzheimer's disease |
| Q40347090 | Transgenic potato expressing Abeta reduce Abeta burden in Alzheimer's disease mouse model |
| Q30438004 | Type 2 diabetes and Alzheimer's disease: from common pathologies to potential new therapeutics |
| Q38836859 | Ultraviolet light triggers the conversion of Cu2+-bound Aβ42 aggregates into cytotoxic species in a copper chelation-independent manner |
| Q93060745 | Unique α-synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression |
| Q22242414 | Vitamin A and Alzheimer's disease |
| Q53276850 | Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology. |
| Q39125887 | Wild-type, Flemish, and Dutch amyloid-β exhibit different cytotoxicities depending on Aβ40 to Aβ42 interaction time and concentration ratio. |
| Q55222634 | Zinc ion rapidly induces toxic, off-pathway amyloid-β oligomers distinct from amyloid-β derived diffusible ligands in Alzheimer's disease. |
| Q36813933 | miR-186 is decreased in aged brain and suppresses BACE1 expression |
| Q34635580 | {gamma}-Secretase Substrate Concentration Modulates the Abeta42/Abeta40 Ratio: IMPLICATIONS FOR ALZHEIMER DISEASE. |
| Q47705574 | β-Sheet Breaker Peptide-HPYD for the Treatment of Alzheimer's Disease: Primary Studies on Behavioral Test and Transcriptional Profiling |
| Q91581374 | γ-Secretase and its modulators: Twenty years and beyond |
| Q39545955 | γ-Secretase complexes containing caspase-cleaved presenilin-1 increase intracellular Aβ(42) /Aβ(40) ratio |
| Q26830462 | γ-Secretase inhibitors and modulators |
| Q35071626 | γ-Secretase processing and effects of γ-secretase inhibitors and modulators on long Aβ peptides in cells |
Search more.